Dynavax (NASDAQ: DVAX) said it regained full rights to DV1179, an investigational bifunctional inhibitor of toll-like receptors (TLR) 7 and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE